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Background/objectives: This paper is part of the international consensus guidelines on chronic pancre-
atitis, presenting for interventional endoscopy.
Methods: An international working group with experts on interventional endoscopy evaluated 26
statements generated from evidence on 9 clinically relevant questions. The Grading of Recommendations
Assessment, Development, and Evaluation approach was used to evaluate the level of evidence. To
determine the level of agreement, a nine-point Likert scale was used for voting on the statements.
Results: Strong consensus was obtained for 15 statements relating to nine questions including the
recommendation that endoscopic intervention should be offered to patients with persistent severe pain
but not to those without pain. Endoscopic decompression of the pancreatic duct could be used for im-
mediate pain relief, and then offered surgery if this fails or needs repeated endoscopy. Endoscopic
drainage is preferred for portal-splenic vein thrombosis and pancreatic fistula. A plastic stent should be
placed and replaced 2e3 months later after insertion. Endoscopic extraction is indicated for stone
fragments remaining after ESWL. Interventional treatment should be performed for symptomatic/
complicated pancreatic pseudocysts. Endoscopic treatment is recommended for bile duct obstruction
and afterwards surgery if this fails or needs repeated endoscopy. Surgery may be offered if there is
significant calcification and/or mass of the pancreatic head. Percutaneous endovascular treatment is
preferred for hemosuccus pancreaticus. Surgical treatment is recommended for duodenal stenosis due to
chronic pancreatitis.
Conclusions: This international expert consensus guideline provides evidenced-based statements con-
cerning indications and key aspects for interventional endoscopy in the management of patients with
chronic pancreatitis.
© 2020 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Interventions for chronic pancreatitis (CP) may include endos-
copy and extracorporeal shock wave lithotripsy (ESWL) as well as
surgery, but with a wide variation in practice globally for these
various approaches [1,2]. There are several guidelines focusing on
interventional endoscopy in chronic pancreatitis [3e7]. However,
these previous guidelines on CP have tended to be based on one
professional group and/or a single geographical area. The purpose
of these guidelines was to provide internationally applicable rec-
ommendations for practicing clinicians on the indication, selection
and approaches for non-surgical interventions. Multidisciplinary
experts from the International Association of Pancreatology, the
American Pancreatic Association, the Japan Pancreas Society, and
European Pancreatic Club (IAP-APA-JPS-EPC) joined to minimize
intrinsic biases for making The International Consensus Guidelines
on Chronic Pancreatitis (ICGCP). This paper aimed to be part of the
international consensus guidelines on chronic pancreatitis, pre-
senting for interventional endoscopy.
Methods
The process for developing the ICGCP guidelines was
commenced at the EPC Annual Meeting of 2016. A team of world-
wide experts comprising gastroenterologists, surgeons and radi-
ologists with expertise in endoscopy and interventional radiology
as well as surgery was composed, chaired by Masayuki Kitano. In-
ternational experts were selected from members of ICGCP Com-
mittee composed of four societies: EPC, APA, JPS and IAP
(Supplementary table). The first step was to generate clinical
questions and evaluate the evidence. A literature review of invited
expert reviews, systematic reviews, and landmark papers that were
published on CP was performed by 11 guideline members (MK,
TMG, PKG, TI, AI, HI, AK, KT, IY, SI, TS). The 11 guideline members
raised as many clinical questions as possible, and consolidated
them to a smaller number. For each clinical question, several
statements were made. The Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) approach was used toevaluate the level of evidence per statement (see http://www.
uptodate.com/home/gradingtutorial). Quality assessment of evi-
dence was graded as ‘high’ if there was (very) low probability of
further research substantially changing the conclusions, ‘moderate’
if further research might completely change the conclusions, and
‘low’ if further research was likely to completely change the con-
clusions. Statements were revised by discussion among all guide-
line members for each domain requiring multiple iterations until
there was complete agreement. Overlapping concepts in different
statements were consolidated into a smaller number of statements.
The strengths of the recommendation were graded as ‘strong’ if it
was very certain that benefits outweigh risks and burdens, ‘weak’ if
risks and burdens appear to be finely balanced, or when benefits,
risks, and burdens are closely balanced or uncertain, or ‘condi-
tional’ if it was in between strong and weak recommendation.
After grading, theworking group of all guidelinemembers voted
on each statement for strength of agreement, using a nine-point
Likert scale. A single round of voting was completed using an
anonymized web-based system, and statements were not further
modified following voting. Out of the results, a Cronbach’s alpha
reliability coefficient was calculated per statement (http://hdl.
handle.net/1805/344). The voting results were classified for
agreement as either; ‘strong’ if 80% of votes were 7 or above,
‘conditional’ if 65%e80% of votes were 7 or above, and ‘weak’ less
than 65% of votes were 7 or above. In addition, comments to each
question and statements were compiled to explain the surrounding
issues, supported by key references.
Results
Q 1: What are the indications for intervention in chronic
pancreatitis.
Statement 1.1. Endoscopic or surgical treatment should be
offered to patients with chronic pancreatitis with persistent
severe pain. Intervention in the form of either surgery or
endotherapy is not recommended in asymptomatic patients
with chronic pancreatitis who do not have abdominal pain to
improve pancreatic exocrine and/or endocrine function or
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Quality assessment: moderate
Recommendation: strong
Agreement: strong
a ¼ 1.00
Statement 1.2. Endoscopic or surgical treatment should be
carried out after careful patient selection for local complica-
tions of chronic pancreatitis with persistent clinical symptoms
such as gastric outlet obstruction, duodenal stenosis, biliary
obstruction with cholestasis and pseudocysts.
Quality assessment: moderate
Recommendation: strong
Agreement: strong
a ¼ 1.00
Statement 1.3. Celiac plexus block may be undertaken in
patients for significant abdominal pain who are not candidates
for pancreatic surgery, or have not responded to endotherapy
and extracorporeal shock wave lithotripsy (ESWL), or have a
poor general condition as a temporizing measure before
definitive therapy.
Quality assessment: moderate
Recommendation: weak
Agreement: weak
a ¼ 0.41
Comment
Although pain is the reason for intervention and key to deciding
timing and type of intervention there is no consensus on how to
assess pain in chronic pancreatitis, but there are several recom-
mendations by the ICGCP for the understanding and management
of pain in chronic pancreatitis [1]. In the clinical situation pain will
normally be rated on an eleven-point numerical scale ranging from
0 (no pain at all) to 10 (worst imaginable pain). Pain characteristics
requiring intervention are that (1) there should be a plausible
relationship between pain and ductal morphology as in large
pancreatic duct disease, (2) the pain is persistent and continuous
with or without exacerbations, (3) that medical treatment is not
successful, and (4) that pain should at last for more than three
months. The likelihood for successful treatment depends on many
factors including age, duration of disease, pain characteristics, and
opioid dependency [2]. Persistent severe pain requires that it
should last for >3 months (i.e. chronic pain according to the new
ICD-11 guidelines), and whilst pain is a composite of sensory in-
tensity, cognitive and affective factors that need to be taken into
consideration for the individual patient, but pain intensity above 3
on the numerical scale with impact on daily life is normally
considered severe [8]. Many factors can bring on pancreatic pain
and shall be considered in the evaluation [9]. Long pain duration
may affect the outcome in a negative way as the sensory system can
undergo permanent neuroplastic changes where pain may become
independent on the peripheral nociceptive drive [10]. More
importantly a temporal association between the development of
pancreatic morphological changes and pain may predict a favorable
prognosis to invasive treatments [2].
It is the general impression that patients with central sensiti-
zation do not respond adequately to treatment [10]. However,
central sensitization is difficult to measure and although quanti-
tative sensory testing, electrophysiological and imaging methods
may reveal some proxies for permanent neuroplastic changes in
the central nervous system, there are no accepted criteria to eval-
uate these findings. Other factors such as anxiety and cognitive
features goes hand in hand with central sensitization and compli-
cates evaluation of the individual patient [1]. Narcotic dependence
normally goes hand in hand with long-lasting pain and centralsensitization and opioid use is associated with a less favorable
outcome [11,12]. It is also of concern that opioids can in some in-
stances contribute to hyperalgesia [8,13]. However, in the individ-
ual patient, it is difficult to determine whether opioids worsen the
response to treatment as these patients have more severe pain and
lower quality of life. This predicts a bad outcome to treatment per
se and complicates the evaluation [2].
Once medical measures have failed, persistent severe pain can
treated by both endoscopic and surgical procedures, although
pancreatic function may not always be improved [14e21]. Early
surgery in two randomized trials was associated with an increased
likelihood of complete pain relief associated with a reduced risk of
pancreatic insufficiency and low re-intervention rates compared to
endoscopic intervention [20,21]. Symptomatic local complications
of chronic pancreatitis including gastric outlet obstruction,
duodenal stenosis, biliary obstruction with cholestasis and pseu-
docysts are also indications for interventional treatment
[15,19e22].
Celiac plexus block (CPB) consists of injecting corticosteroids,
local anesthetics or absolute alcohol into the celiac plexus nerve/
ganglia to disrupt the signaling of painful stimuli through pancre-
atic nerves [23]. Meta-analyses have reported that EUS-guided CPB
may relieve pain in 51%e59% of patients but this is short-lived and
is inferior to surgical management [24e26]. The nerve destruction
may lead to an increase in pain due to neuropathic mechanisms
that develop later and there are potential severe side effects such as
hypotension, hemorrhage, infections and neurological complica-
tions [2,27]. CPB lasts for <3 months and after the neurolysis any
neuropathic pain will worsen and together with the potential se-
vere side effects neurolysis is a contraindication in chronic
pancreatitis [28]. Therefore, we were unable to reach a consensus
about CPB for management of pain in patients with chronic
pancreatitis.
Q 2: What is the best strategy for the treatment of pancreatic
ductal stricture.
Statement 2.1. Non-surgical decompression of the main
pancreatic duct including endoscopic therapy can be selected
for immediate pain relief of chronic pancreatitis before
considering surgery. Surgical intervention should be considered
if endoscopic procedure fails or has temporary success needing
repeated endoscopic therapy.
Quality assessment: moderate
Recommendation: conditional
Agreement: strong
a ¼ 0.88
Statement 2.2. If there are contraindications for surgical
therapy in patients in whom conventional endoscopic therapy
has failed, endosonographic-guided drainage of the pancreatic
duct is another option for pain control.
Quality assessment: moderate
Recommendation: weak
Agreement: weak
a ¼ 0.47
Statement 2.3. Endoscopic drainage should be the preferred
modality for treating pancreatic pain and biliary stricture in
patients with chronic pancreatitis who have associated portal/
splenic vein thrombosis.
Quality assessment: moderate
Recommendation: conditional
Agreement: strong
a ¼ 0.82
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The main purpose of main pancreatic duct (MPD) decompres-
sion is pain relief [29e38]. The immediate response rates with
endoscopic stenting range from 65% to 95% [16,18,29e38].
Morbidity rates of 18%e58% and mortality rates of 0e5% are re-
ported for both endoscopy and surgery [11,20,21,39e43]. The long-
termpain relief is 54% at 2 years [5], 85% at 2e12 years [29], 64% at 2
years [18], and 58% at 12 years [36]. Failed stone extraction using
endoscopic pancreatic sphincterotomy and a basket or a balloon is
associated with stones >10 mm, diffuse location, stone impaction,
and location upstream from a stricture [44,45]. The success rate of
endoscopic therapy is much higher for strictures and stones in the
head of the pancreas than either the body and/or the tail of the
pancreas [4,19].
Three randomized trials demonstrated that surgery is more
effective than endoscopic treatment for persistent pain relief
[20,21,43,47]. In the randomized controlled study from the Czech
Republic, the initial success rates were similar for both groups, but
at the 5-years, absence of pain weight gain were more frequent in
the surgical group although the partial relief of pain and new-onset
diabetes mellitus were not significantly different [20]. In the ran-
domized trial from the Netherlands, symptomatic patients who
underwent endoscopic treatment as the initial treatment for MPD
obstruction had less pain relief (32% vs 75%, at 2 years; 38% vs 80%,
at 5 years respectively), withmore procedures (median of 12 versus
4 at 5 years respectively), than patients whowere treated surgically
[21,43]. Moreover, 47% of the patients in the endoscopy group
eventually underwent surgery after 5-years follow-up [44]. The
ESCAPE multicenter, randomized trial comprised 88 patients with
chronic pancreatitis, a dilated MPD, and who had only recently
started using prescribed opioids for severe pain (strong opioids for
2 months or weak opioids for 6 months) [46]. In the early sur-
gery group 44 patients underwent pancreatic drainage surgery
within 6 weeks after randomization and in the endoscopy-first
approach group 44 patients were randomized to medical treat-
ment, endoscopy including lithotripsy if needed, and surgery if
needed. During 18 months of follow-up, patients in the early sur-
gery group had a lower Izbicki pain score than patients in the group
randomized to receive the endoscopy-first approach group (37
versus 49. Complete or partial pain relief at end of follow-up was
achieved in 23 (58%) of 40 patients with early surgery compared
to16 (39%) of 41 in the endoscopy-first group. The total number of
interventions was lower in the early surgery group, although
treatment complications, mortality (0%), hospital admissions,
pancreatic function, and quality of life were not significantly
different between early surgery and the endoscopy-first approach
[46]. Hirota et al. also found that endoscopic stent placement when
necessary for more than one year, was inferior to surgery [47].
These studies require cautious interpretation pending controlled
sham clinical trials [2].
In complex cases when surgical and conventional endotherapy
are not possible, then EUS -guided drainage of the MPD may be an
option for pain control with an overall clinical success rate of 78.8%,
but the adverse event rate (abdominal pain, bleeding, perforation,
fever and severe pancreatitis) of 18.9% with a median (range) stent
patency of 195 (10e780) days [48e54]. More recent developments
include the use of a dedicated plastic stent or a fully covered self-
expandable metal stent (FCSEMS) [55,56]. EUS-guided drainage of
the MPD should only be performed at a center of expertise, pref-
erably in the context of a clinical trial.
Splanchnic venous thrombosis including splenic vein, hepatic
portal vein and mesenteric vein thrombosis leading to extrahepatic
portal hypertension in patients with CP has prevalence of around
11.6% [57]. Endoscopic therapy may be appropriate in this situationas venous collaterals confer a major risk of complications from
surgery [58].
Q 3: How should endoscopic stent treatment be done for
pancreatic ductal stricture.
Statement 3.1. A straight plastic pancreatic stent should be
placed across the stricture depending on the caliber of the
stricture of the pancreatic duct.
Quality assessment: low
Recommendation: conditional
Agreement: strong
a ¼ 0.88
Statement 3.2. An endoscopic retrograde cholangio-
pancreatography (ERCP) inserted endoscopic stent should be
removed or exchanged at between 2 and 3 months later. At this
time a new stent should be inserted if there is still a significant
stricture.
Quality assessment: low
Recommendation: conditional
Agreement: strong
a ¼ 0.88
Statement 3.3. Multiple stents or a metal stent may be
considered for persisting pancreatic strictures due to severe
chronic pancreatitis.
Quality assessment: low
Recommendation: conditional
Agreement: weak
a ¼ 0.47
Comment
Around 36% of patients who receive pancreatic stenting develop
ductal changes, which are related either to stent occlusion and
direct stent trauma or side branch occlusion [59,60]. Stent
replacement is commonly performed 2e6 months after the initial
stent insertion and not be for >1 year [30e34,36e38,43,47,61e65].
Multiple plastic stents [35], or a removable FCSEMS have been
used to try to achieve quicker stricture resolution [66e68]. Cos-
tamagna et al. found that after a median of three plastic stents (8.5-
Fr to 11-Fr) placed for a mean of 7 months resulted in 84% of pa-
tients being asymptomatic without major complications during a
mean follow-up of 38 months [35]. FCSEMS placement for 2e3
months produced complete pain relief in 86% at a mean follow-up
of 5 months after stent removal but there was a high stent migra-
tion rate [66e68]. However, we were unable to reach a consensus
about multiple stents or a metal stent for treatment of persisting
pancreatic strictures due to severe chronic pancreatitis, because
these previous studies were non-randomized.
Q4: What is the strategy for the treatment of pancreatic ductal
stones.
Statement 4.1. ESWL should be the first-line therapy as non-
surgical intervention for main pancreatic duct stones in pa-
tients with chronic pancreatitis who do not get adequate pain
relief with conservative management although a stent place-
ment may be done first to relieve pain.
Quality assessment: low
Recommendation: conditional
Agreement: conditional
a ¼ 0.71
Statement 4.2. Endoscopic extraction is indicated for small
stones or stone fragments after ESWL.
Quality assessment: moderate
Recommendation: conditional
Agreement: strong
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ESWL for MPD stones >5 mm has achieved complete pain relief
in 52.7% of patients who failed conservative pain management and
mild to moderate pain relief in 33.4% at a median (range) of 24
(2e60) months follow-up [69]. Quality of life improved in 88.2%
and complete ductal clearance was achieved in 70.7% patients [69].
Adverse events from ESWL can be achieved in <6.0% of patients
treated [14,70,71].
A randomized controlled study that compared ESWL alone with
ESWL plus endoscopic stent placement revealed no difference be-
tween the groups neither in terms of MPD diameter decrease, nor
in the number of pain episodes/year [70]. Endoscopic intervention
alone for pancreatic duct stones has a low success rate and a high
complication rate [72]. There are however some studies that
showed that combined ESWL and endoscopic therapy might pro-
vide favorable long-term results [73], even with coexisting
pancreatic pseudocysts [74]. Intraductal laser or electrohydraulic
lithotripsy is another option, but success rates vary from 47% to 89%
[75,76]. Although there was no study comparing ESWL and intra-
ductal therapies for treatment of pancreatic stones, intraductal
therapies require insertion of a pancreatoscope into the pancreatic
duct [77e81]. Further study is needed to decide whether these
intraductal therapies can replace ESWL as first-line treatment.
Q5: What is the strategy for the treatment of pancreatic pseu-
docysts in chronic pancreatitis.
Statement 5.1. For pancreatic pseudocysts that cause symp-
toms and/or complications, interventional or surgical treatment
should be performed.
Quality assessment: moderate
Recommendation: strong
Agreement: strong
a ¼ 0.94
Statement 5.2. Underlying stricture or disruption of themain
pancreatic duct with symptoms and/or complications should be
treated with endoscopic transpapillary placement of a pancre-
atic stent for pseudocysts <5 cm and with communication with
the main pancreatic duct.
Quality assessment: moderate
Recommendation: conditional
Agreement: conditional
a ¼ 0.71
Statement 5.3. Asymptomatic and uncomplicated pancreatic
pseudocysts of more than 5 cm in diameter that do not resolve
within six weeks may be treated with transmural drainage.
Quality assessment: low
Recommendation: weak
Agreement: weak
a ¼ 0.53
Statement 5.4. In case of a suspected neoplastic cystic lesion
diagnostic needle aspiration of the cyst may be done.
Quality assessment: low
Recommendation: weak
Agreement: weak
a ¼ 0.53
Statement 5.5. Surgical intervention should be considered if
endoscopic drainage of pseudocysts fails or has temporary
success needing repeated endoscopic therapy, especially when
there is disconnected duct syndrome, inflammatory mass, and
intraductal calculi with duct strictures.
Quality assessment: low
Recommendation: conditionalAgreement: strong
a ¼ 0.82
Comment
Pancreatic pseudocysts occur in 20% and 40% of patients with CP
[82]. Potential complications of the pseudocysts include infection of
the pseudocyst, bile duct or gastric outflow obstruction or duodenal
stenosis, rupture into the peritoneal cavity, pancreato-pleural fis-
tula, portal or splenic vein thrombosis leading to sinistral (left-
sided) portal hypertension, pseudocyst erosion into adjacent ves-
sels resulting in pseudoaneurysm formation, and bleeding into the
gastrointestinal tract or peritoneal cavity [82,83]. MPD disruption
and stricture may lead to delayed resolution or recurrence of
pancreatic pseudocyst in patients with CP.
Pancreatic duct stenting may improve clinical outcomes in pa-
tients with pancreatic duct stricture or leakage [84]. When the
pseudocyst communicates with the MPD, transpapillary approach
is initially recommended. This approach is useful for drainage of
pseudocysts measuring <5 cm that are not suitable for transmural
drainage [85]. Therefore, if pancreatic duct stricture or disruption is
suspected on imaging tests such as CT and MRI, then endoscopic
retrograde pancreatography (ERP) is recommended with pancre-
atic duct stenting across the stricture or disruption prior to pseu-
docyst drainage. In cases with large pseudocysts however, ERP may
be difficult owing to the severe luminal compression of the stomach
or duodenum, so transmural drainage should be performed first.
For larger pseudocysts, endoscopic transmural drainage has a
technical success rate of more than 90% and a treatment success
rate of 75e90% [86]. For transmural drainage, EUS-guided drainage
has mostly replaced conventional endoscopy-guided drainage, as
needle puncture can be made more accurately and more safely by
avoiding any interposed vessel under real-time color Doppler
guidance [87,88].
Spontaneous resolution of pseudocysts in patients with CP may
occur in around 20% of cases whilst independent predictive factors
of persisting symptoms are intrapancreatic pseudocysts greater
than 4 cm or if they are extra-pancreatic [89]. Indications for pro-
phylactic pseudocyst drainage in the absence of symptoms include
compression of major vessels, pancreato-pleural fistula, pseudocyst
size >5 cmwithout any regression after >6 weeks, pseudocyst wall
>5 mm, and pseudocysts associated with advanced MPD changes
or pancreatolithiasis [3,4]. However, we were unable to reach a
consensus about transmural drainage for asymptomatic and un-
complicated pancreatic pseudocysts of more than 5 cm in diameter
because of low level of evidence.
Differentiation between a pseudocyst and a cystic pancreatic
neoplasm is essential [90e92]. The pooled sensitivity (54%) for
diagnostic needle aspiration of the cyst is low, with a 2.7%
morbidity rate [93,94]. Therefore, we were unable to reach a
consensus about diagnostic needle aspiration of the cyst for a
suspected neoplastic cystic lesion.
There are four randomized trials comparing endoscopic with
surgical intervention that showed that both approaches provided
similarly effective treatment for the pancreatic pseudocysts with no
significant differences in mortality [87,88,95,96]. Endoscopic
drainage was superior in terms of short-term quality of life, dura-
tion of hospital stay, the frequency of adverse events, and hospital
costs, although there was a greater need for additional invasive
procedures with endoscopy-based compared to open surgical
drainage. Endoscopic drainage may be preferred to surgical treat-
ment in symptomatic or complicated non-hemorrhagic pancreatic
pseudocysts [5,82,84,97,98]. Endoscopic drainage of hemorrhagic
pseudocysts is contraindicated requiring a combined endovascular
and surgical approach [3,5,82]. Surgery should be undertaken if
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Q6: What is the strategy for the treatment of distal main biliary
duct obstruction in chronic pancreatitis.
Statement 6.1. Endoscopic treatment is recommended when
the patients show symptoms related to the distal bile duct
obstruction (obstructive jaundice and/or acute cholangitis), and
in persistent cholestasis with alkaline phosphatase elevation
(>2e3 times) for at least month even in asymptomatic patients.
Quality assessment: low
Recommendation: conditional
Agreement: strong
a ¼ 0.88
Statement 6.2. Endoscopic treatment withmultiple plastic or
covered metal stents may be effective for relieving of the
symptoms related to the distal bile duct obstruction due to
chronic pancreatitis.
Quality assessment: low
Recommendation: weak
Agreement: conditional
a ¼ 0.71
Statement 6.3. In main biliary duct strictures caused by
chronic pancreatitis, biliary stent placement is recommended
for a period of 6 months to 1 year.
Quality assessment: low
Recommendation: weak
Agreement: Weak
a ¼ 0.65
Statement 6.4. Plastic stent replacement formain biliary duct
stricture is recommended every 3 months. The optimal period
for replacement of covered metal stent is currently unknown.
Quality assessment: low
Recommendation: weak
Agreement: Conditional
a ¼ 0.71
Statement 6.5. Endoscopic placement of multiple plastic or
covered metal stent and/or surgery are appropriate to manage
refractory bile duct obstruction.
Quality assessment: low
Recommendation: conditional
Agreement: conditional
a ¼ 0.76
Statement 6.6. Surgical treatment should be planned if bile
duct obstruction reoccurs after one year of endoscopic stent
treatment. For the patients who have significant calcifications
and/or mass of the pancreatic head, surgical treatment may be
preferred as an initial treatment.
Quality assessment: low
Recommendation: strong
Agreement: strong
a ¼ 0.94
Comment
Asymptomatic cholestasis due to intra-pancreatic bile duct
stricture may improve spontaneously during observation, but sec-
ondary biliary cirrhosis may develop due to continuous cholestasis
[15]. Endoscopic stenting for biliary decompression is required in
patients with CP presenting with a  4-week history of biliary
obstructionwith jaundice, and/or asymptomatic elevation of serum
alkaline phosphatase >2 times the upper limit of normal [4]. Smits
et al. reported good short-term results, but only 27.6% long-term
success [33]. Calcific pancreatitis is a predictive factor for failure
of initial treatment with single plastic stent, and in these cases,
surgical treatment is preferred as an initial treatment [99,100].Multiple plastic stents [101,102], or a covered SEMS may be used to
manage the refractory cases [66,103,104]. Endoscopic biliary
stenting has no additional effect beyond one year [3,4,33,104e106].
Surgical treatment should therefore be planned if bile duct
obstruction recurs after one year of stent therapy [105,106]. Early
surgical intervention benefits patients in terms of better pain
control and preservation of pancreatic function [40,46,107]. A
resection must be undertaken if malignancy cannot be excluded.
Biliary stricture in calcified CP is difficult to resolve [99,100].
Randomized studies have shown better efficacy of SEMS compared
to multiple plastic stents in treating benign biliary strictures and
need be exchanged every 3e12 months [108,109]. However, there
were low level of evidence about how we should perform endo-
scopic treatment for main biliary duct obstruction in chronic
pancreatitis. In particular, we were unable to reach a consensus
about the duration of stent placement.
Q7: What is the strategy for the treatment of internal pancreatic
fistula and pancreatic pleural effusion and ascites in chronic
pancreatitis.
Statement 7.1. Endoscopic interventional therapy should be
undertaken for themanagement of internal pancreatic fistula in
patients presenting with main pancreatic duct disruption or
obstruction.
Quality assessment: low
Recommendation: conditional
Agreement: Strong
a ¼ 0.88
Comment
Endoscopic interventional therapy for internal pancreatic fis-
tulas such as pancreato-peritoneal and pancreato-pleural fistulas in
CP, includes trans-papillary pancreatic stenting, and endoscopic
sealing of pancreac fistula using glue [110e113]. Early bridging of
the MPD by pancreatic stent can lead to satisfactory outcome
provided this is done before the internal fistula develops are per-
manent fistula tract by granulation tissue and fibrosis [113]. Sur-
gical therapy will be required in patients with complete MPD
obstruction or disruption, or when there is an established internal
fistula [110].
Q8: What is the strategy for the treatment of hemosuccus
pancreaticus in chronic pancreatitis.
Statement 8.1 Percutaneous endovascular treatment should
be the first choice of treatment for hemosuccus pancreaticus in
hemodynamically stable patients. However, patients with he-
modynamic instability and unsuccessful embolization should
undergo surgery.
Quality assessment: low
Recommendation: conditional
Agreement: strong
a ¼ 0.94
Comment
Hemosuccus pancreaticus is a rare form of intermittent gastro-
intestinal blood loss, defined as bleeding into the duodenum from
an internal vascular fistula between a vein or an artery with the
MPD, most commonly due to a pseudoaneurysm [114,115]. Endo-
vascular therapy is preferred ahead of surgery although placing a
stent in the MPD may also work in blocking the fistula. The success
rate of angiographic embolization as the initial therapy is over 70%
whilst surgery tends to be nearly always successful there is a small
risk of post-operative death [115,116].
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obstruction in chronic pancreatitis.
Statement 9.1. Surgical treatment is recommended for
duodenal stenosis associated with chronic pancreatitis, as
endoscopic treatment is difficult in such cases.
Quality assessment: moderate
Recommendation: conditional
Agreement: strong
a ¼ 0.88
Statement 9.2. Duodenal stenosis due to chronic pancreatitis
should be carefully differentiated from pancreatic cancer.
Quality assessment: moderate
Recommendation: strong
Agreement: strong
a ¼ 1.00
Comment
Around 5% of patients with CP have duodenal stenosis due to
inflammation of the pancreatic head or groove pancreatitis, which
occurs locally in the groove formed by the duodenum, pancreatic
head, and common bile duct [15,117]. Groove pancreatitis accounts
for around 6% of CP cases and up to 20% of patients with CP who are
treated by partial pancreaticoduodenectomy [117]. ERCP is techni-
cally challenging in bile or pancreatic duct stenosis with concurrent
duodenum stenosis[44], and EUS-guided drainage of the MPD or
themain biliary duct may be an alternative approach [118]. Surgical
intervention is preferred in patients with biliary and pancreatic
duct strictures due to CP accompanied by duodenal stenosis but
cancer must be excluded [15,119].
Discussion
The aim of the ICGCP (EPC-APA-JPS-IAP) is not only to assist a
more pragmatic basis for patient diagnosis andmanagementbut also
to help accelerate the assessment and hence the development of
newer pharmacological and other therapies. The advantage of ICGCP
over the other guidelines is to provide internationally applicable
recommendations. Regarding interventional endoscopy, previous
guidelines on CP have tended to be based on one professional group
and/ora singlegeographical area [17e20]. By tacklingevidencebased
multi-disciplinary approach across different professional organiza-
tions and different continents intrinsic biases can be minimized. In
addition, most previous guidelines included interventional endos-
copy as a part of therapy. Therefore, detailed statements for inter-
ventional endoscopy were not described in these guidelines. The
European Society of Gastrointestinal Endoscopy (ESGE) reported
guidelines specific to interventional endoscopy on CP, in which
statements for indications, strategy and methods were created only
by endoscopists. The current guidelines of ICGCP are different from
ESGE guidelines in that surgeons and endoscopists from all major
continents contributed to creating detailed statements.
Nine key clinically relevant questions with 26 statements were
eventually chosen to be evaluated. Of these a strong consensus was
obtained for 15 statements relating to nine questions (Table 1). A key
recommendation was that intervention either non-surgical or sur-
gical should be offered to all patients with persistent severe pain and
large duct disease refractory to medical management. This is in line
with the ICGCP guidelines for surgery and the timing of intervention
in CP [120]. Even so at present there is no consensus on how to assess
pain in CP [1,2,8,9]. Whilst many factors can bring on pancreatic pain
[9], previous ICGCP guidelines have made a number several recom-
mendations for the understanding andmanagementof pain in CP [1].
It is important to recognize that long term opioid use is associated
with pain of long duration and is associated with a less favorableoutcome in part due to central sensitization [11,12,107]. Intervention
whether by endoscopic therapy or surgery is better undertaken
sooner rather than later. Early surgery for pain is especially effective
[11,40,46]. Surgery is also an effective treatment for pancreatic ductal
stones compared to endoscopy therapy [20,21]. Non-surgical
decompression of the MPD however could be used for immediate
pain relief, and then the patient offered surgery if this failed. Endo-
scopic drainage is preferred for biliary stricture if there is associated
hepatic portal-splenic vein thrombosis. In terms of endoscopic
techniques, a straight plastic stent should be placed across a
pancreatic stricture and stricture dilatation could thenbeundertaken
dependingonthedegreeofnarrowing;anendoscopic stent shouldbe
removed or replaced 2e3 months later after insertion; and endo-
scopic extraction is indicated for stone fragments following ESWL.
Patientswitha symptomaticpancreaticpseudocyst and/orassociated
with complications should be offered surgical or non-surgical inter-
vention. Endoscopic treatment is recommended for obstructive
jaundice and/or acute cholangitis due to distal bile duct obstruction
and then surgery if this fails. Surgery may be offered if there is sig-
nificant calcification and/or mass of the pancreatic head. Endoscopic
intervention is preferred for an internal pancreatic fistula. Percuta-
neous endovascular treatment is preferred for hemosuccus pan-
creaticus. A duodenum preserving head resection is recommended
for duodenal stenosis due to a CP in the head of the pancreas.
Although there was a strong recommendation for the use of
endoscopic treatment for obstructive jaundice and/or acute chol-
angitis due to distal bile duct obstruction, there was only condi-
tional agreement for the use of biliary stents to manage
uncomplicated or even refractory bile duct obstruction. There was
also conditional agreement on all three statements relating to how
endoscopic biliary drainage could technically be best achieved.
Therewas conditional support for the use of ESWLwithMPD stones
in patients to relieve pain who do not obtain adequate pain relief
with pancreatic duct stent placement. Conditional support high-
lights the need for more focused research on these questions.
There was strong support that symptomatic pancreatic pseu-
docyst should be offered surgical and/or non-surgical intervention.
There was however, only conditional support using endoscopic
pancreatic stents for pseudocysts <5 cm, irrespective of associated
strictures and other features. Also there was only weak support for
transmural drainage of asymptomatic and uncomplicated pancre-
atic pseudocysts >5 cm in diameter that do not resolve within six
weeks, or diagnostic needle aspiration of suspected neoplastic
cystic lesion in the presence of CP.
There was only weak agreement on the use of celiac plexus
block to be undertaken in patients with significant abdominal pain
who are not candidates for pancreatic surgery, or in thosewho have
not responded to endotherapy and ESWL, or in those who have a
poor general condition as a temporizing measure before definitive
therapy. Pain relief only lasts for short term with a risk for side
effects such as postural hypotension and diarrhea [28]. Another
major concern is that the use of celiac plexus block can cause severe
inflammation and fibrosis making subsequent surgery quite diffi-
cult and so celiac plexus block should be abandoned, in line with
the ICGCP consensus guidelines for the understanding and man-
agement of pain in CP [1]. There was weak agreement
endosonographic-guided drainage of the pancreatic duct is an op-
tion for pain control even if there are contraindications for surgical
therapy in patients in whom conventional endoscopic therapy has
failed. This was based on the fact that evidence to support this
approach is weak, whilst there are potential serious complications.
There was also lack of support for the use of multiple stents or a
metal stent for persisting pancreatic strictures, due to lack of good
evidence. The current evidence base does not support strong rec-
ommendations related to the application of endoscopy or surgery
Table 1
Recommendations stratified according to the a score.
Domain Statement a
score
Quality
assessment
Recommendation Agreement
Q1: What are the indications for intervention in
chronic pancreatitis
1.1 Endoscopic or surgical treatment should be offered to patients
with chronic pancreatitis with persistent severe pain.
Intervention in the form of either surgery or endotherapy is not
recommended in asymptomatic patients with chronic
pancreatitis who do not have abdominal pain to improve
pancreatic exocrine and/or endocrine function or prevent
cancer.
1.00 Moderate Strong Strong
Q1: What are the indications for intervention in
chronic pancreatitis
1.2 Endoscopic or surgical treatment should be carried out after
careful patient selection for local complications of chronic
pancreatitis with persistent clinical symptoms such as gastric
outlet obstruction, duodenal stenosis, biliary obstruction with
cholestasis and pseudocysts
1.00 Moderate Strong Strong
Q9: What is the strategy for the treatment of
duodenal obstruction in chronic pancreatitis.
9.2 Duodenal stenosis due to chronic pancreatitis should be
carefully differentiated from pancreatic cancer.
1.00 Moderate Strong Strong
Q5: What is the strategy for the treatment of
pancreatic pseudocysts in chronic pancreatitis.
5.1 For pancreatic pseudocysts that cause symptoms and/or
complications, interventional or surgical treatment should be
performed.
0.94 Moderate Strong Strong
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.6 Surgical treatment should be planned if bile duct obstruction
reoccurs after one year of endoscopic stent treatment. For the
patients who have significant calcifications and/or mass of the
pancreatic head, surgical treatment may be preferred as an
initial treatment.
0.94 Low Strong Strong
Q8: What is the strategy for the treatment of
hemosuccus pancreaticus in chronic
pancreatitis.
8.1 Percutaneous endovascular treatment should be the first choice
of treatment for hemosuccus pancreaticus in hemodynamically
stable patients. However, patients with hemodynamic
instability and unsuccessful embolization should undergo
surgery.
0.94 Low Conditional Strong
Q 2: What is the best strategy for the treatment of
pancreatic ductal stricture.
2.1 Non-surgical decompression of the main pancreatic duct
including endoscopic therapy can be selected for immediate
pain relief of chronic pancreatitis before considering surgery.
Surgical intervention should be considered if endoscopic
procedure fails or has temporary success needing repeated
endoscopic therapy
0.88 Moderate Conditional Strong
Q 3: How should endoscopic stent treatment be
done for pancreatic ductal stricture.
3.1 A straight plastic pancreatic stent should be placed across the
stricture depending on the caliber of the stricture of the
pancreatic duct.
0.88 Low Conditional Strong
Q 3: How should endoscopic stent treatment be
done for pancreatic ductal stricture.
3.2 An endoscopic retrograde cholangio-pancreatography (ERCP)
inserted endoscopic stent should be removed or exchanged at
between 2 and 3 months later. At this time a new stent should
be inserted if there is still a significant stricture.
0.88 Low Conditional Strong
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.1 Endoscopic treatment is recommended when the patients
show symptoms related to the distal bile duct obstruction
(obstructive jaundice and/or acute cholangitis), and in
persistent cholestasis with alkaline phosphatase elevation (>2
e3 times) for at least month even in asymptomatic patients.
0.88 Low Conditional Strong
Q7: What is the strategy for the treatment of
internal pancreatic fistula and pancreatic pleural
effusion and ascites in chronic pancreatitis.
7.1 Endoscopic interventional therapy should be undertaken for
the management of internal pancreatic fistula in patients
presentingwithmain pancreatic duct disruption or obstruction.
0.88 Low Conditional Strong
Q9: What is the strategy for the treatment of
duodenal obstruction in chronic pancreatitis.
9.1 Surgical treatment is recommended for duodenal stenosis
associated with chronic pancreatitis, as endoscopic treatment is
difficult in such cases.
0.88 Moderate Conditional Strong
Q 2: What is the best strategy for the treatment of
pancreatic ductal stricture.
2.3 Endoscopic drainage should be the preferred modality for
treating pancreatic pain and biliary stricture in patients with
chronic pancreatitis who have associated portal/splenic vein
thrombosis.
0.82 Moderate Conditional Strong
Q4: What is the strategy for the treatment of
pancreatic ductal stones.
4.2 Endoscopic extraction is indicated for small stones or stone
fragments after ESWL.
0.82 Moderate Conditional Strong
Q5: What is the strategy for the treatment of
pancreatic pseudocysts in chronic pancreatitis.
5.5 Surgical intervention should be considered if endoscopic
drainage of pseudocysts fails or has temporary success needing
repeated endoscopic therapy, especially when there is
disconnected duct syndrome, inflammatory mass, and
intraductal calculi with duct strictures.
0.82 Low Conditional Strong
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.5 Endoscopic placement of multiple plastic or covered metal
stent and/or surgery are appropriate to manage refractory bile
duct obstruction.
0.76 Low Conditional Conditional
Q4: What is the strategy for the treatment of
pancreatic ductal stones.
4.1 ESWL should be the first-line therapy as non-surgical
intervention for main pancreatic duct stones in patients with
chronic pancreatitis who do not get adequate pain relief with
conservative management although a stent placement may be
done first to relieve pain.
0.71 Low Conditional Conditional
Q5: What is the strategy for the treatment of
pancreatic pseudocysts in chronic pancreatitis.
5.2 Underlying stricture or disruption of the main pancreatic duct
with symptoms and/or complications should be treated with
endoscopic transpapillary placement of a pancreatic stent for
0.71 Moderate Conditional Conditional
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Table 1 (continued )
Domain Statement a
score
Quality
assessment
Recommendation Agreement
pseudocysts <5 cm and with communication with the main
pancreatic duct.
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.2 Endoscopic treatment with multiple plastic or covered metal
stents may be effective for relieving of the symptoms related to
the distal bile duct obstruction due to chronic pancreatitis.
0.71 Low Weak Conditional
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.4 Plastic stent replacement for main biliary duct stricture is
recommended every 3 months. The optimal period for
replacement of covered metal stent is currently unknown.
0.71 Low Weak Conditional
Q6: What is the strategy for the treatment of distal
main biliary duct obstruction in chronic
pancreatitis.
6.3 In main biliary duct strictures caused by chronic pancreatitis,
biliary stent placement is recommended for a period of 6
months to 1 year.
0.65 Low Weak Weak
Q5: What is the strategy for the treatment of
pancreatic pseudocysts in chronic pancreatitis.
5.3 Asymptomatic and uncomplicated pancreatic pseudocysts of
more than 5 cm in diameter that do not resolve within six
weeks may be treated with transmural drainage.
0.53 Low Weak Weak
Q5: What is the strategy for the treatment of
pancreatic pseudocysts in chronic pancreatitis.
5.4 In case of a suspected neoplastic cystic lesion diagnostic needle
aspiration of the cyst may be done.
0.53 Low Weak Weak
Q 2: What is the best strategy for the treatment of
pancreatic ductal stricture.
2.2 If there are contraindications for surgical therapy in patients in
whom conventional endoscopic therapy has failed,
endosonographic-guided drainage of the pancreatic duct is
another option for pain control.
0.47 Moderate Weak Weak
Q 3: How should endoscopic stent treatment be
done for pancreatic ductal stricture.
3.3 Multiple stents or a metal stent may be considered for
persisting pancreatic strictures due to severe chronic
pancreatitis.
0.47 Low Conditional Weak
Q1: What are the indications for intervention in
chronic pancreatitis.
1.3 Celiac plexus block may be undertaken in patients for
significant abdominal pain who are not candidates for
pancreatic surgery or have not responded to endotherapy and
extracorporeal shock wave lithotripsy (ESWL), or have a poor
general condition as a temporizing measure before definitive
therapy.
0.41 Moderate Weak Weak
M. Kitano et al. / Pancreatology 20 (2020) 1045e1055 1053for different subsets of CP (eg, multifocal strictures, large calcific
burden, etc.), and that randomized controlled trial level data are
needed.
Clinical practice should be consolidated around the strong rec-
ommendations. Where the recommendations are weak clinical
practice should be curtailed or substantially modified, unless new
good evidence emerges. Interventions with conditional support
should be considered focus areas for active research to produce
further quality evidence to strengthen the particular clinical
approach.
Declaration of competing interest
All authors have no conflict of interest of these consensus
guidelines.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.pan.2020.05.022.
References
[1] Drewes AM, Bouwense SAW, Campbell CM, Ceyhan GO, Delhaye M, Demir IE,
et al. Working group for the International (IAP e APA e JPS e EPC) Consensus
Guidelines for Chronic Pancreatitis. Guidelines for the understanding and
management of pain in chronic pancreatitis. Pancreatology 2018;18(4):
446e57.
[2] Drewes AM, Kempeneers MA, Andersen DK, Arendt-Nielsen L, Besselink MG,
Boermeester MA, et al. Controversies on the endoscopic and surgical man-
agement of pain in patients with chronic pancreatitis: pros and cons! Gut
2019;68(8):1343e51.
[3] Hoffmeister A, Mayerle J, Beglinger C, Büchler MW, Bufler P, Dathe K, et al.
English language version of the S3-consensus guidelines on chronic
pancreatitis: definition, aetiology, diagnostic examinations, medical, endo-
scopic and surgical management of chronic pancreatitis. Z Gastroenterol
2015;53:1447e95.
[4] Dumonceau JM, Delhaye M, Tringali A, Arvanitakis M, Sanchez-Yague A,
Vaysse T, et al. Endoscopic treatment of chronic pancreatitis: Europeansociety of gastrointestinal endoscopy (ESGE) guideline - updated august
2018. Endoscopy 2019;51(2):179e93.
[5] Frulloni L, Falconi M, Gabbrielli A, Gaia E, Graziani R, Pezzilli R, et al. Italian
consensus guidelines for chronic pancreatitis. Dig Liver Dis 2010;42(Suppl
6):S381e406.
[6] Ito T, Ishiguro H, Ohara H, Kamisawa T, Sakagami J, Sata N, et al. Evidence-
based clinical practice guidelines for chronic pancreatitis 2015.
J Gastroenterol 2016;51:85e92.
[7] Dominguez-Munoz JE, Drewes AM, Lindkvist B, Ewald N, Czako L,
Rosendahl J, et al. HaPanEU/UEG Working Group. Recommendations from
the United European Gastroenterology evidence-based guidelines for the
diagnosis and therapy of chronic pancreatitis. Pancreatology 2018;18:
847e54.
[8] Drewes AM, Olesen AE, Farmer AD, Szigethy E, Rebours V, Olesen SS.
Gastrointestinal pain. Nat Rev Dis Primers 2020;6(1):1. 2020 Jan 6.
[9] Teo K, Johnson MH, Truter S, Pandanaboyana S, Windsor JA. Pain assessment
in chronic pancreatitis: a comparative review of methods. Pancreatology
2016;16(6):931e9.
[10] Arendt-Nielsen L, Morlion B, Perrot S, Dahan A, Dickenson A, Kress HG, et al.
Assessment and manifestation of central sensitisation across different
chronic pain conditions. Eur J Pain 2018;22(2):216e41.
[11] Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH, Gooszen HG, van Dam RM,
Busch OR, et al. Dutch Pancreatitis Study Group. Clinical outcome in relation
to timing of surgery in chronic pancreatitis: a nomogram to predict pain
relief. Arch Surg 2012;147(10):925e32.
[12] Olesen SS, Poulsen JL, Broberg MC, Madzak A, Drewes AM. Opioid treatment
and hypoalbuminemia are associated with increased hospitalisation rates in
chronic pancreatitis outpatients. Pancreatology 2016;16(5):807e13.
[13] Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and
non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol
2018;15:168e80.
[14] Tadenuma H, Ishihara T, Yamaguchi T, et al. Long-term results of extracor-
poreal shockwave lithotripsy and endoscopictherapy for pancreatic stones.
Clin Gastroenterol Hepatol 2005;3:1128e35.
[15] Kleeff J, Neoptolemos J, Whitcomb D, Gress T, Rebours V, Esposito I, et al.
Chronic pancreatitis. Nature Reviews Disease Primers 2017. https://doi.org/
10.1038/nrdp.2017.60. Article number: 17060.
[16] R€osch T, Daniel S, Scholz M, Huibregtse K, Smits M, Schneider T, et al.
Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000
patients with long-term follow-up. Endoscopy 2002;34:765e71.
[17] Inui K, Tazuma S, Yamaguchi T, Ohara H, Tsuji T, Miyagawa H, et al. Treat-
ment of pancreatic stones with extracorporeal shock wave lithotripsy: re-
sults of a multicenter survey. Pancreas 2005;30:26e30.
[18] Delhaye M, Arvanitakis M, Verset G, Cremer M, Deviere J. Long-term clinical
outcome after endoscopic pancreatic ductal drainage for patients with
painful chronic pancreatitis. Clin Gastroenterol Hepatol 2004;2:1096e106.
M. Kitano et al. / Pancreatology 20 (2020) 1045e10551054[19] Dawod E, Kahaleh M. Management of benign and malignant pancreatic duct
strictures. Clin Endosc 2018;51(2):156e60.
[20] Díte P, Ruzicka M, Zboril V, Novotny I. A prospective, randomized trial
comparing endoscopic and surgical therapy for chronic pancreatitis.
Endoscopy 2003;35(7):553e8.
[21] Cahen DL, Gouma DJ, Nio Y, Rauws EA, Boermeester MA, Busch OR, et al.
Endoscopic versus surgical drainage of the pancreatic duct in chronic
pancreatitis. N Engl J Med 2007;356(7):676e84.
[22] Gurusamy KS, Pallari E, Hawkins N, Pereira SP, Davidson BR. Management
strategies for pancreatic pseudocysts. Cochrane Database Syst Rev 2016;4:
CD011392 [online].
[23] Pateman J, WilliamsMP Filshie J. Retroperitoneal fibrosis after multiple
coeliac plexus blocks. Anaesthesia 1990;45:309e10.
[24] Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac
plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer
pain: a meta-analysis and systematic review. Dig Dis Sci 2009;54:2330e7.
[25] Kaufman M, Singh G, Das S, Concha-Parra R, Erber J, Micames C, et al. Efficacy
of endoscopic ultrasound guided celiac plexus block and celiac plexus neu-
rolysis for managing abdominal pain associated with chronic pancreatitis
and pancreatic cancer. J Clin Gastroenterol 2010;44:127e34.
[26] Gress F, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G. Endoscopic
ultrasound-guided celiac plexus block for managing abdominal pain asso-
ciated with chronic pancreatitis: a prospective single center experience. Am J
Gastroenterol 2001;96:409e16.
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